Rutul Shah Biography and Net Worth

COO of Precigen

Mr. Rutul R. Shah serves as Chief Operating Officer for Precigen. Mr. Shah has broad experience in alliance management, portfolio management, program and project management and operations. Prior to joining Precigen, Mr. Shah spent more than a decade in scientific positions focused on the development of protein, antibody, gene and cell therapy drugs at Zyngenia, Teva Biopharmaceuticals USA, CoGenesys, and Human Genome Sciences. Mr. Shah graduated with a BE degree in Chemical Engineering from Gujarat University in India and MS degree in Bioengineering from the University of Illinois, Chicago.

What is Rutul R. Shah's net worth?: The estimated net worth of Rutul R. Shah is at least $1.52 million as of September 26th, 2025. Mr. Shah owns 405,959 shares of Precigen stock worth more than $1,522,346 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Shah may own. Additionally, Mr. Shah receives an annual salary of $453,020.00 as COO at Precigen. Learn More about Rutul R. Shah's net worth.
How old is Rutul R. Shah?: Mr. Shah is currently 43 years old. There are 7 older executives and no younger executives at Precigen. The oldest executive at Precigen is Mr. Randal J. Kirk J.D., Executive Chairman, who is 71 years old. Learn More on Rutul R. Shah's age.
What is Rutul R. Shah's salary?: As the COO of Precigen, Inc., Mr. Shah earns $453,020.00 per year. There are 4 executives that earn more than Mr. Shah. The highest earning executive at Precigen is Dr. Helen Sabzevari MPH, Ph.D., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Rutul R. Shah's salary.
How do I contact Rutul R. Shah?: The corporate mailing address for Mr. Shah and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Rutul R. Shah's contact information.
Has Rutul R. Shah been buying or selling shares of Precigen?: Rutul R. Shah has not been actively trading shares of Precigen during the last ninety days. Most recently, on Friday, September 26th, Rutul R. Shah bought 2,000 shares of Precigen stock. The stock was acquired at an average cost of $3.40 per share, with a total value of $6,800.00. Following the completion of the transaction, the chief operating officer now directly owns 405,959 shares of the company's stock, valued at $1,380,260.60. Learn More on Rutul R. Shah's trading history.
Who are Precigen's active insiders?: Precigen's insider roster includes Nancy Agee (Director), Steven Frank (Director), Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), Rutul Shah (COO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?: In the last year, Precigen insiders bought shares 6 times. They purchased a total of 54,221 shares worth more than $214,466.77. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 9,950,572 shares worth more than $37,720,436.60. The most recent insider tranaction occured on November, 21st when Director Randal J Kirk sold 937,308 shares worth more than $3,589,889.64. Insiders at Precigen own 47.1% of the company. Learn More about insider trades at Precigen.
Information on this page was last updated on 11/21/2025.

Rutul R. Shah Insider Trading History at Precigen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/26/2025	Buy	2,000	$3.40	$6,800.00	405,959
8/24/2023	Sell	5,388	$1.64	$8,836.32	133,474
8/17/2023	Sell	5,298	$1.55	$8,211.90	123,382
8/10/2023	Sell	5,429	$1.21	$6,569.09	113,200
8/3/2023	Sell	5,328	$1.20	$6,393.60	103,149
1/27/2023	Buy	9,142	$1.75	$15,998.50	62,037

Rutul R. Shah Buying and Selling Activity at Precigen

Precigen Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Today's Range

Now: $3.75

$3.51

$3.81

50 Day Range

MA: $3.81

$3.12

$4.90

2 Week Range

Now: $3.75

$0.65

$5.22

Volume

1,906,648 shs

Average Volume

4,272,557 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Rutul Shah Biography and Net Worth

What is Rutul R. Shah's net worth?

How old is Rutul R. Shah?

What is Rutul R. Shah's salary?

How do I contact Rutul R. Shah?

Has Rutul R. Shah been buying or selling shares of Precigen?

Who are Precigen's active insiders?

Are insiders buying or selling shares of Precigen?